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Abstract
Previously, we have shown that systemically administered 
radiolabeled interleukin la  (IL-la) accumulates preferen­
tially in inflammatory foci in mice. Since inflammation is 
characterized by influx of leukocytes, which represent IL-1 
receptor (IL-1R) positive cells, radiolabeled IL-1 may spe­
cifically localize in inflammation by binding to its receptors 
on infiltrated leukocytes. This hypothesis was tested in a se­
ries of studies in mice with acute focal inflammations. Evi­
dence for specific IL-l-IL-lR interaction in induced inflam­
mation was found: microscopic autoradiography revealed 
that 125I-IL-la localized at the site of inflammatory cells 
with time; 125I-myoglobin, a similar-sized protein with no 
known interactions in vivo, was not retained in the inflam­
mation. Furthermore, the uptake 125I-IL-la in inflamma­
tory tissue was significantly lower in neutropenic mice than 
in immunocompetent mice (0.05 ±0.004 vs. 0.65 ±0.06% ID/g 
at 48 h after injection, P < 0.0007). Moreover, the uptake of 
*25I-IL-la at the inflammatory site could be blocked with 
the anti-IL-lR type II antibody 4E2. At 48 h after injection, 
the uptake with and without blocking the type IIIL-1R was 
0.13±0.01 and 0.65±0.05% ID/g, respectively (P < 0.0001). 
These in vivo studies provide evidence that systemically ad­
ministered radiolabeled IL-la localizes in inflammatory tis­
sue by specific receptor binding, predominantly by binding
to the type IIIL-1R. (X Clin. Invest 1997. 100:2970-2976.) 
Key words: leukocytic infiltration • mice • microscopic auto­
radiography • neutropenia * receptor blockade
Introduction
IL-1 is a 17-kD protein, produced by monocytes as a response 
to endotoxin. Two forms of IL-1, IL-la and IL-lß, have been 
discovered, binding to two types of receptors on a wide variety 
of cells. The type I IL-1 receptor (IL-1R), a 80-kD glycopro­
tein, is found on T cells, fibroblasts, hepatocytes, and endothe-
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liai cells, whereas B cells, macrophages, monocytes, and neu­
trophils express the 68-kD type II IL-1R (1). IL-1 binds to 
both receptors with affinity in the picomolar range (2 ).
Since infection and inflammation are characterized by in­
flux of predominantly IL-1R positive leukocytes, systemically 
administered IL-1 may preferentially localize in inflammatory 
tissue by means of specific receptor binding. Recently, local­
ization of radiolabeled IL-la in Staphylococcus aureus-induced 
infections in mice was demonstrated (3). It cleared rapidly 
from noninflamed tissues,
Receptor binding of IL-1 to murine leukocytes has been 
well characterized both in vitro and ex vivo (2 ,4, 5). However, 
in vivo in mice, receptor binding has not been demonstrated 
directly but only indirectly via inhibition of IL-l-induced bio­
logic activity by blockade of type I IL-lRs (6-10). In vivo bind­
ing to type II IL-lRs could not be shown due to lack of effect 
of type II IL-1R blockade on biologic activity (10). The 
present paper describes a series of studies conducted to vali­
date the hypothesis of specific receptor binding of IL-la in 
inflammation in mice. Binding of systemically administered 
IL-la to type I as well as type II IL-'lRs was investigated by 
antibody-blocking studies. Our studies demonstrate localiza­
tion of IL-la in inflammatory tissue by specific binding to type II 
IL-lRs on locally present infiltrated leukocytes,
Methods
A4ice. Female Swiss mice weighing 20-25 g (Harlan Netherlands B.V., 
Zeist, The Netherlands) were kept in cages (5-15 mice per cage) and 
fed standard laboratory chow and water ad libitum.
Reagents. Human recombinant IL-la (specific activity of 3 X 108 
U/mg) was kindly provided by Dr. P. Lomedico (Hoffman-La Roche, 
Nutley, NJ). Myoglobin was purchased from Sigma Chemical Co. (St. 
Louis, MO). The anti-IL-lR type I antibody (35F5) and the anti—IL-1 R 
type II antibody (4E2) (both monoclonal rat IgG) were prepared at 
Hoffmann-LaRoche.
Radioiodination. IL-la and IL-lß were radiolabeled using the io- 
dogen method (11). In brief, for microscopic autoradiography studies,
10 jjLg IL-la (0.68 mg/ml) in 10 (jlI 0.5 M and 80 |jlI 50 mM phosphate 
buffer, pH 7.2, and 111 MBq Nal25I (Amersham International, Amer­
sham, UK; specific activity of 570 GBq/mg) were added to glass 
tubes, precoated with 25 jjLg of l,3,4,6-tetrachloro-3a,6a-diphenylglu- 
couril (Pierce, Rockford, IL). For all other studies, 3 |xg IL-la (0.68 
mg/mi) or 3 jjug IL-lß (1 mg/ml) was labeled with 15-20 MBq Na125I. 
The reaction was allowed to proceed for 10 min at room temperature, 
after which the reaction mixture was eluted with 0.5% BSA in PBS 
on a Sephadex column (PD-10; Pharmacia, Uppsala, Sweden) to sep­
arate labeled IL-la and IL-lß from free 125I. The void fractions were 
pooled and sterilized through a 0.2-(im filter.
Analogously, 10 juLg myoglobin (1 mg/ml), a protein with a molec­
ular mass (18 kD) similar to IL-la and IL-lß without any known in­
teractions in vivo, was labeled with Na125I.
The labeling efficiency of IL-la, IL-lß, and myoglobin was be­
tween 50 and 80%. For the microscopic autoradiography studies,
2970 van der Laken et al.
both IL-la and myoglobin were labeled with Na,25I at a specific activ­
ity of 8-12 MBq/fxg. The specific activity used in all other studies was 
3-4 MBq/|xg.
The radiochemical purity of the radiolabeled proteins was deter­
mined by instant thin-layer chromatography (ITLC) on Gelman 
ITLC-SG strips (Gelman Laboratories, Ann Arbor, MI) with 0.1 M 
citrate, pH 5.0, as the solvent. The radiochemical purity of all radiola­
beled proteins was > 96% after removal of unbound iodine.
Typically, the receptor binding fraction and the dissociation con­
stant of radioiodinated IL-1 preparations were 70-95% and 5 X 10M1 
mol/liter, respectively, as determined on the murine cell line EL-4-6.1, 
a variant subline of EL-4 thymoma cells (12), a kind gift of Dr. H.R. 
MacDonald (Ludwig Institute for Cancer Research, Epalinges, Swit­
zerland) (3).
Mouse model of inflammation. Focal inflammations in the left 
calf muscles of ether anesthetized mice were induced either with 2 X
n
107 colony forming units of S. aureus in 0.05 ml 50-50% suspension of 
autologous blood and normal saline or with 0.05 ml 7.5% zymosan in 
sterile saline. In some experiments, before the induction of focal in­
flammation (day 0), neutropenia (< 109 white blood cells/liter) was 
induced in mice by repeated subcutaneous injections of cyclophos­
phamide: 150 mg/kg body wt in 200 jjlI saline on day “ 4 and 100 mg/ 
kg on day -1.24 h after the induction of inflammation, when swelling 
of the muscle was apparent, mice were injected with l25I-IL-la, 123I~ 
IL-lß, free 125I, or with the nonspecific control agent 125I-myoglobin 
(microscopic autoradiography) in the tail vein.
Microscopic autoradiography. At 2, 6, and 24 h after intravenous 
injection of 0.2 ml 2 jxg 24 MBq l25I-IL-la or 2 \xg 24 MBq t25I-myo- 
globin (24 h after injection only), groups of three mice were killed 
under ether anesthesia by cervical dislocation. S. aureus-induced 
inflammations and contralateral noninflamed calf muscles were 
dissected. After removal, excised tissues were immediately fixed in 
4% buffered formalin and embedded in paraffin, Four sections of 4 p,m 
were cut of each excised tissue and mounted on glass slides by con­
ventional procedures. The sections were deparaffinized with xylene 
and hydrated by passage through serial dilutions of ethanol. Subse­
quently, slides were dipped in hypercoat LM1 photographic emulsion 
(Amersham) in the dark room. The slides were exposed in light-tight 
boxes for 3-4 wk at 4°C. After exposure, the emulsions were devel­
oped with Kodak D-19 developer (4 min), washed in water (20 s), and 
fixed in 24% thiosulfate (wt/vol, 4 min). The slides were slightly post­
stained with hematoxylin. Parallel series of slides stained with hema­
toxylin and eosin without photographic emulsion were included for 
belter appreciation of morphology.
The autoradiographs were quantitated by automated image anal­
ysis (13). 10 high power fields per inflammation section, i.e.» 5 fields in 
the area of the cellular infiltration and 5 fields in the area of the unaf­
fected muscle, were selected. Furthermore, five fields per contralat­
eral muscle were selected. The number of grains per field was deter­
mined. The mean number of grains per field was calculated for Lhe 
different areas in the tissue.
Ex vivo tissue biodistribution. Mice were killed under ether anes­
thesia by cervical dislocation at 5 min, Ï, 2, 6,12,24, and 48 h after in­
jection of 125I-IL-la, 125I-IL-lß, or free 125I. Blood samples, inflamed 
left calf muscle, right calf muscle, thymus, lungs, spleen, liver, and 
kidneys were collected. The dissected tissues were weighed and 
counted in the gamma counter. To correct for radioactive decay, in­
jection standards were counted simultaneously. The measured radio­
activity in tissues and samples was expressed as percentage of in­
jected radioactivity dose per gram of tissue (% ID/g).
Statistical analysis. All values are expressed as meaniSEM. Sta­
tistical analysis was performed using the one-way ANOVA.
Results
The uptake o f125f-IL-la in inflammation in the course of time. 
The blood clearance and uptake in inflammation of 12SI-I.L-la 
and free 1251 was determined in mice with S. aureus-induced in­
flammation at various time points (n = 5 for each preparation 
per time point) after intravenous injection of 0.4 MBq 120 ng 
of 125I-IL-la or 0.4 MBq of free 125I. Despite rapid clearance 
from the blood, 125I-IL-la accumulated in the inflammation, 
reaching maximum values of uptake within 2 h after injection 
(Fig. 1 A). 2 h after injection, the uptake of 125I-IL-la in in­
flammation decreased. A  significant level of l25I-IL-la was re­
tained in the inflammatory tissue up to 48 h after injection 
(0.8% ID/g). In contrast, lliI-LL-la levels in the blood continu­
ously decreased to a level <  0.05% ID/g at 48 h after injection. 
12 h after injection, the uptake of 125I-IL-la in inflammation 
was significantly higher than the blood levels (P <  0.005). The 
retention of activity in inflammation with time was due to up­
take of 125I-IL-la and not of free 125I:free I25I rapidly cleared 
from the inflammation in a similar fashion as from the blood 
(Fig. 1 B). To be able to study the specific receptor-binding 
mechanism oí 125I-IL-1 in inflammation, the following studies 
focused on the time span of 12-48 h after injection because of 
high background activity levels at early time points.
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Figure L The blood clear­
ance {open circles) and up­
take in S. aureus-induced 
inflammation (closed cir­
cles) of l2fiI-IL-la (A) and 
free 125 : (B) at various 
time pc ints after injection 
(p.i.). The results are ex­
pressed as percentages 
of injected radioactivity 
dose per gram of tissue 
(% ID/g,. The error bars 
indicate S£M. The blood 
levels of both 125l-IL-la 
and free ,25ï determined 
at 5 min afler injection, 
6.6±0.2 and 8.8±0.3% 
ÏD/g, respectively, were 
left out of the figure for 
clarity.
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Figure 2. The uptake of l25I-IL-Ia and 125I-IL-lß in S. aureus- 
induced inflammation in mice at 24 (striped bars) and 48 h (open 
bars) after injection. The results are expressed as percentages of in­
jected radioactivity dose per gram of tissue (% ID/g), The error bars 
indicate SHM.
Comparison of uptake of ml-ïL-la and ,25l-lL-lß in in­
flammation. The biodistribution of both 125I-IL-la and 125I-IL-lß 
was determined in mice with S. aureus-induced inflammations 
at various time points (n = 5 for each radiolabeled preparation 
per time point) after intravenous injection of 0.4 MBq 120 ng 
of the radiolabeled preparation. The uptake of l25I-IL-la in in­
flammation was higher than of 125I-IL-lß (Fig. 2). At 48 h after 
injection, 0.76±0.11 % ID/g of I25I~IL-la was still found in the 
inflammation, while levels of 125l-IL-lß decreased to 0.15± 
0.01% ID/g at 48 h after injection. From 12 h after injection 
onwards the uptake of 125I-IL-la at the site of inflammation 
was significantly higher than of 1251-IL-lß (P < 0.05). Due to 
the significantly higher uptake of 125I-IL-la in inflammation as 
compared with U5I-IL-lß, further studies exploring the recep­
tor-binding mechanism at the inflammatory site were per­
formed with IL-la.
Microscopic autoradiography. Microscopic autoradiogra­
phy was applied to study whether systemically administered 
radiolabeled IL-la localizes at the site of infiltrated leukocytes 
in induced inflammation in mice. As early as 2 h after injec­
tion, uptake of 125I-IL-la in the inflammation was observed. 
At this time point, most of 125I-IL-la, found in areas of cellular 
infiltration, was Localized around the blood vessels. The radio­
label was also found in the unaffected muscular tissue. With 
time, I25I-IL-la was retained within the cellular infiltration, 
while the uptake in the unaffected muscle tissue decreased. 
After 24 h, nearly all 125I-IL~la was clearly associated with the 
site of inflammatory cells, as demonstrated in Fig. 3,^ 4 and B. 
In contrast, no specific retention of 125I-IL4a was found in the 
contralateral muscle (Fig. 3 C). The size-matched control pro­
tein 125I-myoglobin did not localize at the site of the inflamma­
tory cells (Fig. 3 D).
The above observations were analyzed quantitatively. The 
results are shown in Fig. 4. As early as 2 h after injection, most 
l25I-IL-la was found in the area of the cellular infiltration at
2 h after injection. The number of grains in the contralateral 
muscle and in areas of unaffected muscular tissue in the in­
flammation decreased during the time course of the experi­
ment. Thus, with time, 125I4L4a migrated from the unaffected 
muscle tissue to the inflammatory cells within the inflamma­
tion. After 24 h, nearly all grains in the infection were found in
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the area of cellular infiltration. At all time points, the number 
of grains in the cellular infiltration was significantly higher 
than the number of grains in the adjacent unaffected muscle 
and the contralateral muscle (P < 0.0001). Furthermore, the 
uptake of 125I-IL-la in the area of the cellular infiltration was 
significantly higher than of 125I-myoglobin at 24 h after injec­
tion (P < 0.0001).
Comparison of biodistribution ofI25l-IL-la in immunocom­
petent and neutropenic mice. To study whether the presence 
of cellular infiltration is crucial to localization of radiolabeled 
IL-la in inflammation, effects of neutropenia were investi­
gated and compared with observations in immunocompetent 
mice. Zymosan, instead of S. aureus, was used for induction of 
inflammation in these studies to prevent mortality due to sep­
sis in neutropenic mice. Histology demonstrated that the mas­
sive infiltration of leukocytes, predominantly PMNs, as ob­
served in immunocompetent mice was absent in neutropenic 
mice (data not shown). The biodistribution of 125I-IL-la in im­
munocompetent (n = 25) and neutropenic mice (n = 25), de­
termined at various times after intravenous injection of 0.4 
MBq 120 ng of the radiolabeled preparation, was similar (Ta­
ble I). 125I4L-la rapidly cleared from most organs. However, 
one major difference was observed: l25I4L4a was retained at 
the site of inflammation in immunocompetent mice, while vir­
tually no retention of l2iT-IL4a in the inflammation was found 
in neutropenic mice (Fig. 5). At all time points, the uptake of 
i25I-IL-la at the site of inflammation was significantly higher 
in immunocompetent mice than in neutropenic mice (P < 
0.001). Maximum differences were obtained at 48 h after injec­
tion; the uptake of 125I-IL-la in inflammation was > 12 times 
higher in immunocompetent mice compared with neutropenic 
mice, 0.65±0.06 and 0.05±0.004% ID/g, respectively.
Effect of in vivo blockade of IL-lRs on localization of 
125I-IL-1 a in inflammation. To elucidate whether type I and/ 
or type II 1L4R is/are involved in entrapment of radioiodi- 
nated IL-la in inflammation, groups of five mice with S. au- 
reusAnduced inflammations were injected intravenously with 
200 fjLg anti-type I IL-1R antibody 35F5, 200 (jLg anti-type II 
IL-1R antibody 4E2, or a mixture of both antibodies (200 jxg 
of each antibody) in 100 sterile saline at 6 h and 5 min be­
fore intravenous injection of 0.4 MBq 120 ng 125I4L4a. Con­
trol mice (n = 5) were injected intravenously with 100 \ú ster­
ile saline before injection of l25I-IL-la. As depicted in Fig. 6, 
mice with type IIL-1R blockade displayed significantly higher 
uptake of l25I4L4a in the inflammation than the control 
group, i.e., 2.26±0.12 vs. 0.65±0.05% ID/g at 48 h after injec­
tion (P < 0.0001). In contrast, the uptake of I25I-IL-la at the 
site of inflammation in mice with blockade of type II IL-lRs 
(0.13±0.009) was significantly lower than the value obtained 
in control mice (P < 0.0001). A similar low uptake of 0.1.4±
0.009% ID/g in inflammation was found in mice with both type
I and type IIIL-1R blockade. The l25I4L-la levels in the blood 
and all other organs were similar for all studied groups (data 
not shown).
Discussion
»
This study confirms the hypothesis that systemically adminis­
tered radiolabeled IL-la localizes in acute inflammatory foci 
by specific receptor binding. As demonstrated by microscopic 
autoradiography, IL-la localized within the inflammation at 
the site of the infiltrated leukocytes, which were predomi-
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Figure 5. The uptake of I25I-IL-la in zymosan-induced inflammation 
in neutropenic and immunocompetent mice at 24 (striped bars) and 
48 h (open bars) after injection. The results are expressed as percent­
ages of injected radioactivity dose per gram of tissue (% ID/g). The 
error bars indicate SEM.
mulates in inflammatory tissue by means of binding to its re­
ceptors on infiltrated leukocytes.
The IL-1R blockade studies showed that the binding of ra­
diolabeled IL-la to infiltrated leukocytes was mainly due to 
binding to type II IL-lRs. The inflammation uptake of IL-la 
was significantly lower in case of blockade of type II IL-lRs. 
Surprisingly, increased uptake of radiolabeled IL-la in the in­
flammation was found when type I IL-lRs were blocked. 
Blockade of type I IL-lRs, expressed on a wide range of cells 
in the body, may have increased levels of free IL-la, available 
for binding to type II IL-lRs, expressed on infiltrated neutro­
phils and monocytes in the inflammation. When both type I and 
type II IL-lRs were blocked, inflammation uptake of IL-la 
was as low as that found with type II IL-1R blockade only. 
This indicates that the increased uptake of IL-la in inflamma­
tory tissue (obtained by blockade of type I IL-lRs) could be 
completely inhibited by blockade of type II IL-lRs. Therefore, 
aspecific increased uptake of IL-la in inflammation in case of 
type IIL-1R blockade could be ruled out. Binding to soluble 
type II IL-lRs, increased during various inflammatory condi­
tions (21-23), could also be excluded since the used anti-type
II antibody 4E2 also binds and neutralizes these receptors.
Although blockade of binding of radiolabeled IL-la to 
type II IL-lRs with the antibody 4E2 has been demonstrated 
in vitro on cell lines (24), in vivo, blockade of type II IL-lRs 
did not affect particular studied biologic effects of IL-la (7, 
10). Since it is now generally accepted that the type II IL-1R 
acts as a decoy receptor for IL-1 (25-28), no direct effects of 
type IIIL-1R blockade on IL-1 induced biologic activity are to 
be expected. Indirectly, type II IL-1R blockade may enhance
Table I. Biodistribution of mTIL-1 a in Neutropenic and Immunocompetent Mice with Zymosan-indue ed. Inflammation
Organ Neutropenia 2 h p.i.* 6 h p.i, 12 h p.i. 24 h p.i. 48 h p.i.
Blood + • 4.79±0.19 2.12±0.12 0.52±0.12 0.18±0.01 0.04±0.004
— 4.10±0.33 1.49+0.13 0.28±0.009 0.13 ±0.01 0.08 ±0.009
Inflammation + 1.67 ±0.14 0.96±0.06 0.36±0.04 0.24 ±0.06 0.05 ±0.004
2.90±0.17 2.20±0.05 1.33+0.14 0.96+0.02 0.65 ±0.06
Muscle + 0.77±0.04 0.36±0.04 0.08 ±0.02 0.04 ±0.006 0.01 ±0.002
— 1.18±0.40 0.25 ±0.02 0.08+0.004 0.04+0.002 0.02± 0.004
Thymus + 2.35 ±0.28 1.46 ±0.23 0.35 ±0.10 0.14±0.01 0.07 ±0.02
— 1.38 ±0.22 0.85 ±0.21 0.24 ±0.03 0.12±0.02 0.06±0.004
Lung 3.89 ±0.23 1.86±0.06 0.49±0.14 0.18±0.01 0.06±0.008
— 5.32±0.70 1.45±0.02 0.31 ±0.02 0.14±0.006 0.11 ±0.02
Spleen + 4.70±0.25 1.44 ±0.10 0.38±0.10 0.15±0.006 0.06±0.004
— 4.68±0.64 1.36 ±0.11 0.35 ±0.05 0.14±0.03 0.07±0.009
Liver + 4.67±0.25 1.26±0.06 0.38±0.06 0.19 ±0,02 0.10±0.004
— 3.26±0,28 0.91+0.10 0.32±0.01 0.19+0.01 0.16±0.009
Kidney + 5.27 ±0.26 1.79±0.09 0.58±0.10 0.27±0.01 0.16 ±0.008
4.67±0.45 1.25 ±0.14 0.41 ±0.02 0.26±0.006 0.18±0.01
*A11 values are expressed as percentage of injected dose per gram of tissue, p.i, postinjection.
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Figure 6. The uptake of ^-T-IL-la in inflammation at 48 h after injec­
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II antibodies before injection of i2iiI-IL-la. Control mice weie in­
jected with saline before injection of 125I-IL-la, The results are ex­
pressed as percentages of injected radioactivity dose per gram of tis­
sue (% ID/g). The error bars indicate SEM.
ceptor-bound IL-1 (31) and a fast turnover of the receptor (2 h) 
(32). However, these characteristics were observed in vitro us­
ing the Raji human B lymphoma cell line. In vivo, IL-1 binding 
to type II receptors on activated leukocytes in inflammatory 
tissue may be different.
This study supports first indications that systemically ad­
ministered radiolabeled IL-la localizes in inflammation by 
specific receptor binding. The type II IL-1R appeared to be 
the predominant binding site in acute inflammation models. 
Actual binding of IL-la to type II IL-1R in inflammatory tis­
sue could be demonstrated. Future studies will focus on the in 
vivo behavior of IL-la and the correlation with IL-1 R expres­
sion in various other inflammation models.
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